Cargando…

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solitano, Virginia, D’Amico, Ferdinando, Fiorino, Gionata, Paridaens, Kristine, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564568/ https://www.ncbi.nlm.nih.gov/pubmed/32911840 http://dx.doi.org/10.3390/jcm9092905

Ejemplares similares

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
por: Bencardino, Sarah, et al.
Publicado: (2023)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study
por: Allocca, Mariangela, et al.
Publicado: (2022)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?
por: Solitano, Virginia, et al.
Publicado: (2021)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study
por: Allocca, Mariangela, et al.
Publicado: (2018)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach
por: Danese, Silvio, et al.
Publicado: (2018)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

Early Biological Therapy in Operated Crohn’s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future
por: Solitano, Virginia, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bonovas, Stefanos, et al.
Publicado: (2016)

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
por: D'Amico, Ferdinando, et al.
Publicado: (2020)

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
por: Fiorino, Gionata, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8b6pugb54mc1uqt1mmng366taf